TY - JOUR AU - Kantarjian, H. AU - Thomas, D. AU - O’Brien, S. AU - Cortes, J. AU - Giles, F. AU - Jeha, S. PY - 2004 DA - 2004// TI - Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia JO - Cancer. VL - 101 UR - https://doi.org/10.1002/cncr.20668 DO - 10.1002/cncr.20668 ID - Kantarjian2004 ER - TY - JOUR AU - Rowe, J. M. AU - Buck, G. AU - Burnett, A. K. AU - Chopra, R. AU - Wiernik, P. H. AU - Richards, S. M. PY - 2005 DA - 2005// TI - Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993 JO - Blood. VL - 106 UR - https://doi.org/10.1182/blood-2005-04-1623 DO - 10.1182/blood-2005-04-1623 ID - Rowe2005 ER - TY - JOUR AU - Marks, D. I. AU - Paietta, E. M. AU - Moorman, A. V. AU - Richards, S. M. AU - Buck, G. AU - DeWald, G. PY - 2009 DA - 2009// TI - T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993) JO - Blood. VL - 114 UR - https://doi.org/10.1182/blood-2009-08-231217 DO - 10.1182/blood-2009-08-231217 ID - Marks2009 ER - TY - JOUR AU - Chao, N. J. AU - Blume, K. G. AU - Forman, S. J. AU - Snyder, D. S. PY - 1995 DA - 1995// TI - Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia JO - Blood. VL - 85 UR - https://doi.org/10.1182/blood.V85.11.3353.bloodjournal85113353 DO - 10.1182/blood.V85.11.3353.bloodjournal85113353 ID - Chao1995 ER - TY - JOUR AU - Pui, C. H. AU - Crist, W. M. AU - Look, A. T. PY - 1990 DA - 1990// TI - Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia JO - Blood. VL - 76 UR - https://doi.org/10.1182/blood.V76.8.1449.1449 DO - 10.1182/blood.V76.8.1449.1449 ID - Pui1990 ER - TY - STD TI - Thomas X, Thiebaut A, Olteanu N, Danaila C, Charrin C, Archimbaud E, et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther. 1998;40(3):119–28. ID - ref6 ER - TY - STD TI - Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580. ID - ref7 ER - TY - STD TI - Ribera JM, Oriol A, Morgades M, Montesinos P, Sarra J, Gonzalez-Campos J, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595–604. ID - ref8 ER - TY - JOUR AU - Ravandi, F. AU - O'Brien, S. AU - Thomas, D. AU - Faderl, S. AU - Jones, D. AU - Garris, R. PY - 2010 DA - 2010// TI - First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia JO - Blood. VL - 116 UR - https://doi.org/10.1182/blood-2009-12-261586 DO - 10.1182/blood-2009-12-261586 ID - Ravandi2010 ER - TY - JOUR AU - Daver, N. AU - Thomas, D. AU - Ravandi, F. AU - Cortes, J. AU - Garris, R. AU - Jabbour, E. PY - 2015 DA - 2015// TI - Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia JO - Haematologica. VL - 100 UR - https://doi.org/10.3324/haematol.2014.118588 DO - 10.3324/haematol.2014.118588 ID - Daver2015 ER - TY - JOUR AU - Chalandon, Y. AU - Thomas, X. AU - Hayette, S. AU - Cayuela, J. M. AU - Abbal, C. AU - Huguet, F. PY - 2015 DA - 2015// TI - Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia JO - Blood. VL - 125 UR - https://doi.org/10.1182/blood-2015-02-627935 DO - 10.1182/blood-2015-02-627935 ID - Chalandon2015 ER - TY - JOUR AU - Kantarjian, H. M. AU - DeAngelo, D. J. AU - Stelljes, M. AU - Martinelli, G. AU - Liedtke, M. AU - Stock, W. PY - 2016 DA - 2016// TI - Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1509277 DO - 10.1056/NEJMoa1509277 ID - Kantarjian2016 ER - TY - JOUR AU - Kantarjian, H. AU - Stein, A. AU - Gokbuget, N. AU - Fielding, A. K. AU - Schuh, A. C. AU - Ribera, J. M. PY - 2017 DA - 2017// TI - Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1609783 DO - 10.1056/NEJMoa1609783 ID - Kantarjian2017 ER - TY - JOUR AU - Martinelli, G. AU - Boissel, N. AU - Chevallier, P. AU - Ottmann, O. AU - Gökbuget, N. AU - Topp, M. S. PY - 2017 DA - 2017// TI - Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome–positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.69.3531 DO - 10.1200/JCO.2016.69.3531 ID - Martinelli2017 ER - TY - JOUR AU - Gokbuget, N. AU - Dombret, H. AU - Bonifacio, M. AU - Reichle, A. AU - Graux, C. AU - Faul, C. PY - 2018 DA - 2018// TI - Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia JO - Blood. VL - 131 UR - https://doi.org/10.1182/blood-2017-08-798322 DO - 10.1182/blood-2017-08-798322 ID - Gokbuget2018 ER - TY - JOUR AU - Maude, S. L. AU - Laetsch, T. W. AU - Buechner, J. AU - Rives, S. AU - Boyer, M. AU - Bittencourt, H. PY - 2018 DA - 2018// TI - Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1709866 DO - 10.1056/NEJMoa1709866 ID - Maude2018 ER - TY - JOUR AU - Gokbuget, N. AU - Dombret, H. AU - Ribera, J. M. AU - Fielding, A. K. AU - Advani, A. AU - Bassan, R. PY - 2016 DA - 2016// TI - International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia JO - Haematologica. VL - 101 UR - https://doi.org/10.3324/haematol.2016.144311 DO - 10.3324/haematol.2016.144311 ID - Gokbuget2016 ER - TY - JOUR AU - Fielding, A. K. AU - Richards, S. M. AU - Chopra, R. AU - Lazarus, H. M. AU - Litzow, M. R. AU - Buck, G. PY - 2007 DA - 2007// TI - Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study JO - Blood. VL - 109 UR - https://doi.org/10.1182/blood-2006-05-018192 DO - 10.1182/blood-2006-05-018192 ID - Fielding2007 ER - TY - STD TI - Jabbour E, Pui CH, Kantarjian H. Progress and innovations in the management of adult acute lymphoblastic leukemia. JAMA Oncol. 2018;4(10):1413–20. ID - ref19 ER - TY - JOUR AU - Liu, D. AU - Zhao, J. AU - Song, Y. AU - Luo, X. AU - Yang, T. PY - 2019 DA - 2019// TI - Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0703-z DO - 10.1186/s13045-019-0703-z ID - Liu2019 ER - TY - STD TI - Kantarjian H, Jabbour E. Incorporating immunotherapy into the treatment strategies of B-cell adult acute lymphoblastic leukemia: the role of blinatumomab and inotuzumab ozogamicin. Am Soc Clin Oncol Educ Book. 2018;38:574–8. ID - ref21 ER - TY - JOUR AU - Kantarjian, H. AU - Thomas, D. AU - Jorgensen, J. AU - Kebriaei, P. AU - Jabbour, E. AU - Rytting, M. PY - 2013 DA - 2013// TI - Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia JO - Cancer. VL - 119 UR - https://doi.org/10.1002/cncr.28136 DO - 10.1002/cncr.28136 ID - Kantarjian2013 ER - TY - JOUR AU - DeAngelo, D. J. AU - Stock, W. AU - Stein, A. S. AU - Shustov, A. AU - Liedtke, M. AU - Schiffer, C. A. PY - 2017 DA - 2017// TI - Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study JO - Blood Adv VL - 1 UR - https://doi.org/10.1182/bloodadvances.2016001925 DO - 10.1182/bloodadvances.2016001925 ID - DeAngelo2017 ER - TY - JOUR AU - Kantarjian, H. M. AU - DeAngelo, D. J. AU - Stelljes, M. AU - Liedtke, M. AU - Stock, W. AU - Gökbuget, N. PY - 2019 DA - 2019// TI - Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study JO - Cancer. VL - 125 UR - https://doi.org/10.1002/cncr.32116 DO - 10.1002/cncr.32116 ID - Kantarjian2019 ER - TY - STD TI - Jabbour E, Gökbuget N, Advani AS, Stelljes M, Stock W, Liedtke M, et al. Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial. J Clin Oncol. 2018;36(15_suppl):7013. ID - ref25 ER - TY - JOUR AU - Topp, M. S. AU - Gokbuget, N. AU - Stein, A. S. AU - Zugmaier, G. AU - O’Brien, S. AU - Bargou, R. C. PY - 2015 DA - 2015// TI - Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study JO - The Lancet Oncology VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71170-2 DO - 10.1016/S1470-2045(14)71170-2 ID - Topp2015 ER - TY - STD TI - Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–40. ID - ref27 ER - TY - STD TI - Sasaki K, Kantarjian HM, Ravandi F, Short NJ, Kebriaei P, Huang X, et al. Sequential combination of low-intensity chemotherapy (mini-hyper-CVD) plus inotuzumab ozogamicin with or without blinatumomab in patients with relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL): a phase 2 trial. Blood. 2018;132(Supplement 1):553. ID - ref28 ER - TY - STD TI - Advani AS, Moseley A, Liedtke M, O'Donnell MR, Aldoss I, Mims MP, et al. SWOG 1312 final results: a phase 1 trial of inotuzumab in combination with CVP (cyclophosphamide, vincristine, prednisone) for relapsed/refractory CD22+ acute leukemia. Blood. 2019;134(Supplement_1):227. ID - ref29 ER - TY - STD TI - Lacayo NJ, Pullarkat VA, Stock W, Jabbour E, Bajel A, Rubnitz J, et al. Safety and efficacy of venetoclax in combination with navitoclax in adult and pediatric relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood. 2019;134(Supplement_1):285. ID - ref30 ER - TY - STD TI - Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Sasaki K, et al. Updated results of a phase II study of reduced-intensity chemotherapy with mini-hyper-CVD in combination with inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2019;134(Supplement_1):823. ID - ref31 ER - TY - STD TI - Advani AS, Moseley A, O’Dwyer KM, Wood B, Fang M, Wieduwilt MJ, et al. Results of SWOG 1318: a phase 2 trial of blinatumomab followed by pomp (prednisone, vincristine, methotrexate, 6-mercaptopurine) maintenance in elderly patients with newly diagnosed Philadelphia chromosome negative B-cell acute lymphoblastic leukemia. Blood. 2018;132(Supplement 1):33. ID - ref32 ER - TY - STD TI - Richard-Carpentier G, Kantarjian HM, Short NJ, Ravandi F, Ferrajoli A, Schroeder HM, et al. Updated results from the phase II study of hyper-CVAD in sequential combination with blinatumomab in newly diagnosed adults with B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2019;134(Supplement_1):3807. ID - ref33 ER - TY - STD TI - Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4(2):230–4. ID - ref34 ER - TY - STD TI - Sasaki K, Kantarjian HM, Ravandi F, Short NJ, Kebriaei P, Huang X, et al. Sequential combination of inotuzumab ozogamicin (InO) with low-intensity chemotherapy (mini-hyper-CVD) with or without blinatumomab is highly effective in patients (pts) with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in first relapse. Blood. 2019;134(Supplement_1):3806. ID - ref35 ER - TY - JOUR AU - Geng, H. AU - Brennan, S. AU - Milne, T. A. AU - Chen, W. Y. AU - Li, Y. AU - Hurtz, C. PY - 2012 DA - 2012// TI - Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-12-0208 DO - 10.1158/2159-8290.CD-12-0208 ID - Geng2012 ER - TY - JOUR AU - Alford, S. E. AU - Kothari, A. AU - Loeff, F. C. AU - Eichhorn, J. M. AU - Sakurikar, N. AU - Goselink, H. M. PY - 2015 DA - 2015// TI - BH3 Inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-1849 DO - 10.1158/0008-5472.CAN-14-1849 ID - Alford2015 ER - TY - JOUR AU - Frismantas, V. AU - Dobay, M. P. AU - Rinaldi, A. AU - Tchinda, J. AU - Dunn, S. H. AU - Kunz, J. PY - 2017 DA - 2017// TI - Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia JO - Blood. VL - 129 UR - https://doi.org/10.1182/blood-2016-09-738070 DO - 10.1182/blood-2016-09-738070 ID - Frismantas2017 ER - TY - STD TI - Guerra VA, Jabbour EJ, Ravandi F, Kantarjian H, Short NJ. Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Ther Adv Hematol. 2019;10:2040620719849496. ID - ref39 ER - TY - STD TI - Jain N, Klisovic RB, Stock W, Ungar D, Zeidan AM, Atallah E, et al. Interim data from a phase 1 study evaluating pyrrolobenzodiazepine-based antibody drug conjugate ADCT-402 (loncastuximab tesirine) targeting CD19 for relapsed or refractory B-cell acute lymphoblastic leukemia. Blood. 2017;130(Supplement 1):1321. ID - ref40 ER - TY - JOUR AU - Duell, J. AU - Dittrich, M. AU - Bedke, T. AU - Mueller, T. AU - Eisele, F. AU - Rosenwald, A. PY - 2017 DA - 2017// TI - Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL JO - Leukemia. VL - 31 UR - https://doi.org/10.1038/leu.2017.41 DO - 10.1038/leu.2017.41 ID - Duell2017 ER - TY - JOUR AU - Zhao, J. AU - Song, Y. AU - Liu, D. PY - 2019 DA - 2019// TI - Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0705-x DO - 10.1186/s13045-019-0705-x ID - Zhao2019 ER - TY - STD TI - Grupp SA, Maude SL, Rives S, Baruchel A, Boyer MW, Bittencourt H, et al. Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia. Blood. 2018;132(Supplement 1):895. ID - ref43 ER - TY - JOUR AU - Park, J. H. AU - Riviere, I. AU - Gonen, M. AU - Wang, X. AU - Senechal, B. AU - Curran, K. J. PY - 2018 DA - 2018// TI - Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1709919 DO - 10.1056/NEJMoa1709919 ID - Park2018 ER - TY - STD TI - Short NJ, Kantarjian H, Jabbour E, Ravandi F. Novel therapies for older adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2018;13(2):91–9. ID - ref45 ER - TY - JOUR AU - O'Brien, S. AU - Thomas, D. A. AU - Ravandi, F. AU - Faderl, S. AU - Pierce, S. AU - Kantarjian, H. PY - 2008 DA - 2008// TI - Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia JO - Cancer. VL - 113 UR - https://doi.org/10.1002/cncr.23819 DO - 10.1002/cncr.23819 ID - O'Brien2008 ER - TY - JOUR AU - Gokbuget, N. PY - 2013 DA - 2013// TI - How I treat older patients with ALL JO - Blood. VL - 122 UR - https://doi.org/10.1182/blood-2012-07-379016 DO - 10.1182/blood-2012-07-379016 ID - Gokbuget2013 ER - TY - JOUR AU - Li, S. AU - Molony, J. T. AU - Chia, V. AU - Katz, A. J. PY - 2016 DA - 2016// TI - Patient characteristics and treatment patterns in elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) using 100% Medicare ALL data JO - Blood. VL - 128 UR - https://doi.org/10.1182/blood.V128.22.3981.3981 DO - 10.1182/blood.V128.22.3981.3981 ID - Li2016 ER - TY - JOUR AU - Geyer, M. B. AU - Hsu, M. AU - Devlin, S. M. AU - Tallman, M. S. AU - Douer, D. AU - Park, J. H. PY - 2017 DA - 2017// TI - Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis JO - Blood. VL - 129 UR - https://doi.org/10.1182/blood-2016-11-749507 DO - 10.1182/blood-2016-11-749507 ID - Geyer2017 ER - TY - STD TI - Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240–8. ID - ref50 ER - TY - JOUR AU - Ribeiro, R. C. AU - Abromowitch, M. AU - Raimondi, S. C. AU - Murphy, S. B. AU - Behm, F. AU - Williams, D. L. PY - 1987 DA - 1987// TI - Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia JO - Blood. VL - 70 UR - https://doi.org/10.1182/blood.V70.4.948.948 DO - 10.1182/blood.V70.4.948.948 ID - Ribeiro1987 ER - TY - JOUR AU - Moorman, A. V. AU - Chilton, L. AU - Wilkinson, J. AU - Ensor, H. M. AU - Bown, N. AU - Proctor, S. J. PY - 2010 DA - 2010// TI - A population-based cytogenetic study of adults with acute lymphoblastic leukemia JO - Blood. VL - 115 UR - https://doi.org/10.1182/blood-2009-07-232124 DO - 10.1182/blood-2009-07-232124 ID - Moorman2010 ER - TY - JOUR AU - Fielding, A. K. AU - Rowe, J. M. AU - Buck, G. AU - Foroni, L. AU - Gerrard, G. AU - Litzow, M. R. PY - 2014 DA - 2014// TI - UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia JO - Blood. VL - 123 UR - https://doi.org/10.1182/blood-2013-09-529008 DO - 10.1182/blood-2013-09-529008 ID - Fielding2014 ER - TY - JOUR AU - Ravandi, F. AU - O'Brien, S. M. AU - Cortes, J. E. AU - Thomas, D. M. AU - Garris, R. AU - Faderl, S. PY - 2015 DA - 2015// TI - Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia JO - Cancer. VL - 121 UR - https://doi.org/10.1002/cncr.29646 DO - 10.1002/cncr.29646 ID - Ravandi2015 ER - TY - JOUR AU - Kim, D. Y. AU - Joo, Y. D. AU - Lim, S. N. AU - Kim, S. D. AU - Lee, J. H. AU - Lee, J. H. PY - 2015 DA - 2015// TI - Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia JO - Blood. VL - 126 UR - https://doi.org/10.1182/blood-2015-03-636548 DO - 10.1182/blood-2015-03-636548 ID - Kim2015 ER - TY - STD TI - Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547–55. ID - ref56 ER - TY - STD TI - Short NJ, Kantarjian HM, Ravandi F, Huang X, Daver NG, DiNardo CD, et al. Long-term safety and efficacy of hyper-CVAD plus ponatinib as frontline therapy for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2019;134(Supplement_1):283. ID - ref57 ER - TY - JOUR AU - Rousselot, P. AU - Coude, M. M. AU - Gokbuget, N. AU - Gambacorti Passerini, C. AU - Hayette, S. AU - Cayuela, J. M. PY - 2016 DA - 2016// TI - Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL JO - Blood. VL - 128 UR - https://doi.org/10.1182/blood-2016-02-700153 DO - 10.1182/blood-2016-02-700153 ID - Rousselot2016 ER - TY - JOUR AU - Chiaretti, S. AU - Vitale, A. AU - Elia, L. AU - Fedullo, A. L. AU - Albino, S. AU - Piciocchi, A. PY - 2015 DA - 2015// TI - Multicenter total therapy Gimema LAL 1509 protocol for de novo adult Ph + acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic-based prognostic stratification JO - Blood VL - 126 UR - https://doi.org/10.1182/blood.V126.23.81.81 DO - 10.1182/blood.V126.23.81.81 ID - Chiaretti2015 ER - TY - STD TI - Ottmann OG, Pfeifer H, Cayuela J-M, Spiekermann K, Jung W, Beck J, et al. Nilotinib (Tasigna®) and low intensity chemotherapy for first-line treatment of elderly patients with BCR-ABL1-positive acute lymphoblastic leukemia: final results of a prospective multicenter trial (EWALL-PH02). Blood. 2018;132(Supplement 1):31. ID - ref60 ER - TY - STD TI - Chalandon Y, Rousselot P, Cayuela J-M, Thomas X, Clappier E, Havelange V, et al. Nilotinib combined with lower-intensity chemotherapy for front-line treatment of younger adults with Ph-positive acute lymphoblastic leukemia: interim analysis of the GRAAPH-2014 trial. Eur Hematol Assoc. 2018;2(1):410. ID - ref61 ER - TY - JOUR AU - Vignetti, M. AU - Fazi, P. AU - Cimino, G. AU - Martinelli, G. AU - Raimondo, F. AU - Ferrara, F. PY - 2007 DA - 2007// TI - Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol JO - Blood. VL - 109 UR - https://doi.org/10.1182/blood-2006-10-052746 DO - 10.1182/blood-2006-10-052746 ID - Vignetti2007 ER - TY - JOUR AU - Foa, R. AU - Vitale, A. AU - Vignetti, M. AU - Meloni, G. AU - Guarini, A. AU - Propris, M. S. PY - 2011 DA - 2011// TI - Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia JO - Blood. VL - 118 UR - https://doi.org/10.1182/blood-2011-05-351403 DO - 10.1182/blood-2011-05-351403 ID - Foa2011 ER - TY - STD TI - Martinelli G, Piciocchi A, Papayannidis C, Paolini S, Robustelli V, Soverini S, et al. First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2017;130(Supplement 1):99. ID - ref64 ER - TY - STD TI - Chiaretti S, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo C, et al. Dasatinib-blinatumomab combination for the front-line treatment of adult Ph + ALL patients. Updated results of the Gimema LAL2116 D-Alba trial. Blood. 2019;134(Supplement_1):740. ID - ref65 ER - TY - JOUR AU - Ravandi, F. AU - Jorgensen, J. L. AU - O'Brien, S. M. AU - Jabbour, E. AU - Thomas, D. A. AU - Borthakur, G. PY - 2016 DA - 2016// TI - Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia JO - Br J Haematol VL - 172 UR - https://doi.org/10.1111/bjh.13834 DO - 10.1111/bjh.13834 ID - Ravandi2016 ER - TY - JOUR AU - Short, N. J. AU - Jabbour, E. AU - Sasaki, K. AU - Patel, K. AU - O’Brien, S. M. AU - Cortes, J. E. PY - 2016 DA - 2016// TI - Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia JO - Blood. VL - 128 UR - https://doi.org/10.1182/blood-2016-03-707562 DO - 10.1182/blood-2016-03-707562 ID - Short2016 ER - TY - STD TI - Samra B, Kantarjian HM, Sasaki K, Konopleva MY, Khouri R, O’Brien SM, et al. Discontinuation of tyrosine kinase inhibitors (TKIs) in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Blood. 2019;134(Supplement_1):3819-. ID - ref68 ER - TY - JOUR AU - Pfeifer, H. AU - Wassmann, B. AU - Bethge, W. AU - Dengler, J. AU - Bornhauser, M. AU - Stadler, M. PY - 2013 DA - 2013// TI - Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia JO - Leukemia. VL - 27 UR - https://doi.org/10.1038/leu.2012.352 DO - 10.1038/leu.2012.352 ID - Pfeifer2013 ER - TY - JOUR AU - Carpenter, P. A. AU - Snyder, D. S. AU - Flowers, M. E. AU - Sanders, J. E. AU - Gooley, T. A. AU - Martin, P. J. PY - 2007 DA - 2007// TI - Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia JO - Blood. VL - 109 UR - https://doi.org/10.1182/blood-2006-04-019836 DO - 10.1182/blood-2006-04-019836 ID - Carpenter2007 ER - TY - JOUR AU - Giebel, S. AU - Czyz, A. AU - Ottmann, O. AU - Baron, F. AU - Brissot, E. AU - Ciceri, F. PY - 2016 DA - 2016// TI - Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the acute leukemia working party of the European Society for Blood and Marrow Transplantation JO - Cancer. VL - 122 UR - https://doi.org/10.1002/cncr.30130 DO - 10.1002/cncr.30130 ID - Giebel2016 ER - TY - STD TI - Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela JM, Hayette S, Vekemans MC, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biology Blood Marrow Transplant. 2013;19(1):150–5. ID - ref72 ER - TY - JOUR AU - Piccaluga, P. P. AU - Paolini, S. AU - Martinelli, G. PY - 2007 DA - 2007// TI - Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia JO - Cancer. VL - 110 UR - https://doi.org/10.1002/cncr.22881 DO - 10.1002/cncr.22881 ID - Piccaluga2007 ER - TY - JOUR AU - Ravandi, F. AU - Othus, M. AU - O’Brien, S. M. AU - Forman, S. J. AU - Ha, C. S. AU - Wong, J. Y. C. PY - 2016 DA - 2016// TI - US Intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL JO - Blood Adv VL - 1 UR - https://doi.org/10.1182/bloodadvances.2016001495 DO - 10.1182/bloodadvances.2016001495 ID - Ravandi2016 ER - TY - JOUR AU - Pfeifer, H. AU - Wassmann, B. AU - Pavlova, A. AU - Wunderle, L. AU - Oldenburg, J. AU - Binckebanck, A. PY - 2007 DA - 2007// TI - Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) JO - Blood. VL - 110 UR - https://doi.org/10.1182/blood-2006-11-052373 DO - 10.1182/blood-2006-11-052373 ID - Pfeifer2007 ER - TY - STD TI - Short NJ, Kantarjian HM, Ravandi F, Daver NG, Pemmaraju N, Thomas DA, et al. Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results of a phase II study. J Clin Oncol. 2017;35(15_suppl):7013-. ID - ref76 ER - TY - JOUR AU - Sasaki, K. AU - Jabbour, E. J. AU - Ravandi, F. AU - Short, N. J. AU - Thomas, D. A. AU - Garcia-Manero, G. PY - 2016 DA - 2016// TI - Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis JO - Cancer. VL - 122 UR - https://doi.org/10.1002/cncr.30231 DO - 10.1002/cncr.30231 ID - Sasaki2016 ER - TY - STD TI - Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, et al. Efficacy of ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(4):257–65. ID - ref78 ER - TY - STD TI - Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13(9):936–45. ID - ref79 ER - TY - JOUR AU - Wieduwilt, M. J. AU - Yin, J. AU - Wetzler, M. AU - Uy, G. L. AU - Powell, B. L. AU - Kolitz, J. E. PY - 2016 DA - 2016// TI - A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB study 10701 (Alliance) JO - Blood VL - 128 UR - https://doi.org/10.1182/blood.V128.22.2782.2782 DO - 10.1182/blood.V128.22.2782.2782 ID - Wieduwilt2016 ER - TY - STD TI - Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(12):897–901. ID - ref81 ER - TY - STD TI - Jain N, Cortes JE, Ravandi F, Konopleva M, Alvarado Y, Kadia T, et al. Inotuzumab ozogamicin in combination with bosutinib for patients with relapsed or refractory Ph + ALL or CML in lymphoid blast phase. Blood. 2017;130(Supplement 1):143. ID - ref82 ER - TY - STD TI - Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125–34. ID - ref83 ER - TY - JOUR AU - Jain, N. AU - Roberts, K. G. AU - Jabbour, E. AU - Patel, K. AU - Eterovic, A. K. AU - Chen, K. PY - 2017 DA - 2017// TI - Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults JO - Blood. VL - 129 UR - https://doi.org/10.1182/blood-2016-07-726588 DO - 10.1182/blood-2016-07-726588 ID - Jain2017 ER - TY - STD TI - Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35(4):394–401. ID - ref85 ER - TY - JOUR AU - Mullighan, C. G. AU - Miller, C. B. AU - Radtke, I. AU - Phillips, L. A. AU - Dalton, J. AU - Ma, J. PY - 2008 DA - 2008// TI - BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros JO - Nature. VL - 453 UR - https://doi.org/10.1038/nature06866 DO - 10.1038/nature06866 ID - Mullighan2008 ER - TY - STD TI - Tran TH, Loh ML. Ph-like acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):561–6. ID - ref87 ER - TY - JOUR AU - Roberts, K. G. AU - Li, Y. AU - Payne-Turner, D. AU - Harvey, R. C. AU - Yang, Y. L. AU - Pei, D. PY - 2014 DA - 2014// TI - Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1403088 DO - 10.1056/NEJMoa1403088 ID - Roberts2014 ER - TY - JOUR AU - Jain, N. AU - Lamb, A. V. AU - O’Brien, S. AU - Ravandi, F. AU - Konopleva, M. AU - Jabbour, E. PY - 2016 DA - 2016// TI - Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype JO - Blood. VL - 127 UR - https://doi.org/10.1182/blood-2015-08-661702 DO - 10.1182/blood-2015-08-661702 ID - Jain2016 ER - TY - JOUR AU - Tasian, S. K. AU - Loh, M. L. AU - Hunger, S. P. PY - 2017 DA - 2017// TI - Philadelphia chromosome–like acute lymphoblastic leukemia JO - Blood. VL - 130 UR - https://doi.org/10.1182/blood-2017-06-743252 DO - 10.1182/blood-2017-06-743252 ID - Tasian2017 ER - TY - JOUR AU - Kim, S. -. K. AU - Knight, D. A. AU - Jones, L. R. AU - Vervoort, S. AU - Ng, A. P. AU - Seymour, J. F. PY - 2018 DA - 2018// TI - JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias JO - Genes Dev VL - 32 UR - https://doi.org/10.1101/gad.307504.117 DO - 10.1101/gad.307504.117 ID - Kim2018 ER - TY - JOUR AU - DeAngelo, D. J. AU - Yu, D. AU - Johnson, J. L. AU - Coutre, S. E. AU - Stone, R. M. AU - Stopeck, A. T. PY - 2007 DA - 2007// TI - Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801 JO - Blood. VL - 109 UR - https://doi.org/10.1182/blood-2006-11-056754 DO - 10.1182/blood-2006-11-056754 ID - DeAngelo2007 ER - TY - JOUR AU - Gokbuget, N. AU - Basara, N. AU - Baurmann, H. AU - Beck, J. AU - Bruggemann, M. AU - Diedrich, H. PY - 2011 DA - 2011// TI - High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation JO - Blood. VL - 118 UR - https://doi.org/10.1182/blood-2011-01-329441 DO - 10.1182/blood-2011-01-329441 ID - Gokbuget2011 ER - TY - STD TI - Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, et al. Phase II study of nelarabine (compound 506 U78) in children and young adults with refractory T-cell malignancies: a report from the children’s oncology group. J Clinical Oncol. 2005;23(15):3376–82. ID - ref94 ER - TY - STD TI - Dunsmore KP, Winter S, Devidas M, Wood BL, Esiashvili N, Eisenberg N, et al. COG AALL0434: a randomized trial testing nelarabine in newly diagnosed T-cell malignancy. J Clin Oncol. 2018;36(15_suppl):10500. ID - ref95 ER - TY - STD TI - Dunsmore KP, Devidas M, Linda SB, Borowitz MJ, Winick N, Hunger SP, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol. 2012;30(22):2753–9. ID - ref96 ER - TY - JOUR AU - Abaza, Y. AU - Kantarjian, H. M. AU - Faderl, S. AU - Jabbour, E. AU - Jain, N. AU - Thomas, D. PY - 2018 DA - 2018// TI - Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma JO - Am J Hematol VL - 93 UR - https://doi.org/10.1002/ajh.24947 DO - 10.1002/ajh.24947 ID - Abaza2018 ER - TY - STD TI - Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147–56. ID - ref98 ER - TY - JOUR AU - Neumann, M. AU - Heesch, S. AU - Schlee, C. AU - Schwartz, S. AU - Gokbuget, N. AU - Hoelzer, D. PY - 2013 DA - 2013// TI - Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations JO - Blood. VL - 121 UR - https://doi.org/10.1182/blood-2012-11-465138 DO - 10.1182/blood-2012-11-465138 ID - Neumann2013 ER - TY - JOUR AU - Zhang, J. AU - Ding, L. AU - Holmfeldt, L. AU - Wu, G. AU - Heatley, S. L. AU - Payne-Turner, D. PY - 2012 DA - 2012// TI - The genetic basis of early T-cell precursor acute lymphoblastic leukaemia JO - Nature. VL - 481 UR - https://doi.org/10.1038/nature10725 DO - 10.1038/nature10725 ID - Zhang2012 ER - TY - STD TI - Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, et al. Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study. J Clin Oncol. 2017;35(23):2683–91. ID - ref101 ER - TY - STD TI - Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4(9):1074–87. ID - ref102 ER - TY - STD TI - Jain N, Stevenson KE, Winer ES, Garcia JS, Stone RM, Jabbour E, et al. A multicenter phase I study combining venetoclax with mini-hyper-CVD in older adults with untreated and relapsed/refractory acute lymphoblastic leukemia. Blood. 2019;134(Supplement_1):3867. ID - ref103 ER - TY - JOUR AU - Malard, F. AU - Mohty, M. PY - 2020 DA - 2020// TI - Acute lymphoblastic leukaemia JO - Lancet. VL - 395 UR - https://doi.org/10.1016/S0140-6736(19)33018-1 DO - 10.1016/S0140-6736(19)33018-1 ID - Malard2020 ER - TY - JOUR AU - DeAngelo, D. J. AU - Stevenson, K. E. AU - Dahlberg, S. E. AU - Silverman, L. B. AU - Couban, S. AU - Supko, J. G. PY - 2015 DA - 2015// TI - Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia JO - Leukemia. VL - 29 UR - https://doi.org/10.1038/leu.2014.229 DO - 10.1038/leu.2014.229 ID - DeAngelo2015 ER - TY - JOUR AU - Gökbuget, N. AU - Beck, J. AU - Brandt, K. AU - Brüggemann, M. AU - Burmeister, T. AU - Diedrich, H. PY - 2013 DA - 2013// TI - Significant improvement of outcome in adolescents and young adults (AYAs) aged 15-35 years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protocol; results of 1529 AYAs in 2 consecutive trials of the German multicenter study group for adult ALL (GMALL) JO - Blood. VL - 122 UR - https://doi.org/10.1182/blood.V122.21.839.839 DO - 10.1182/blood.V122.21.839.839 ID - Gökbuget2013 ER - TY - STD TI - Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. 2014;4:e252. ID - ref107 ER - TY - JOUR AU - Hough, R. AU - Rowntree, C. AU - Goulden, N. AU - Mitchell, C. AU - Moorman, A. AU - Wade, R. PY - 2016 DA - 2016// TI - Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003 JO - Br J Haematol VL - 172 UR - https://doi.org/10.1111/bjh.13847 DO - 10.1111/bjh.13847 ID - Hough2016 ER - TY - STD TI - Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911–8. ID - ref109 ER - TY - STD TI - Ribera JM, Oriol A, Sanz MA, Tormo M, Fernandez-Abellan P, del Potro E, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008;26(11):1843–9. ID - ref110 ER - TY - JOUR AU - Storring, J. M. AU - Minden, M. D. AU - Kao, S. AU - Gupta, V. AU - Schuh, A. C. AU - Schimmer, A. D. PY - 2009 DA - 2009// TI - Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen JO - Br J Haematol VL - 146 UR - https://doi.org/10.1111/j.1365-2141.2009.07712.x DO - 10.1111/j.1365-2141.2009.07712.x ID - Storring2009 ER - TY - JOUR AU - Toft, N. AU - Birgens, H. AU - Abrahamsson, J. AU - Griskevicius, L. AU - Hallbook, H. AU - Heyman, M. PY - 2018 DA - 2018// TI - Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia JO - Leukemia. VL - 32 UR - https://doi.org/10.1038/leu.2017.265 DO - 10.1038/leu.2017.265 ID - Toft2018 ER - TY - JOUR AU - Stock, W. AU - Luger, S. M. AU - Advani, A. S. AU - Yin, J. AU - Harvey, R. C. AU - Mullighan, C. G. PY - 2019 DA - 2019// TI - A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 JO - Blood. VL - 133 UR - https://doi.org/10.1182/blood-2018-10-881961 DO - 10.1182/blood-2018-10-881961 ID - Stock2019 ER - TY - JOUR AU - Rytting, M. E. AU - Thomas, D. A. AU - O’Brien, S. M. AU - Ravandi-Kashani, F. AU - Jabbour, E. J. AU - Franklin, A. R. PY - 2014 DA - 2014// TI - Augmented Berlin-Frankfurt-Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) JO - Cancer. VL - 120 UR - https://doi.org/10.1002/cncr.28930 DO - 10.1002/cncr.28930 ID - Rytting2014 ER - TY - JOUR AU - Jabbour, E. AU - O'Brien, S. AU - Ravandi, F. AU - Kantarjian, H. PY - 2015 DA - 2015// TI - Monoclonal antibodies in acute lymphoblastic leukemia JO - Blood. VL - 125 UR - https://doi.org/10.1182/blood-2014-08-596403 DO - 10.1182/blood-2014-08-596403 ID - Jabbour2015 ER - TY - JOUR AU - Hoelzer, D. AU - Walewski, J. AU - Dohner, H. AU - Viardot, A. AU - Hiddemann, W. AU - Spiekermann, K. PY - 2014 DA - 2014// TI - Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial JO - Blood. VL - 124 UR - https://doi.org/10.1182/blood-2014-03-563627 DO - 10.1182/blood-2014-03-563627 ID - Hoelzer2014 ER - TY - JOUR AU - Maury, S. AU - Chevret, S. AU - Thomas, X. AU - Heim, D. AU - Leguay, T. AU - Huguet, F. PY - 2016 DA - 2016// TI - Rituximab in B-lineage adult acute lymphoblastic leukemia JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1605085 DO - 10.1056/NEJMoa1605085 ID - Maury2016 ER - TY - STD TI - Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880–9. ID - ref118 ER - TY - JOUR AU - Thomas, D. A. AU - Faderl, S. AU - O'Brien, S. AU - Bueso-Ramos, C. AU - Cortes, J. AU - Garcia-Manero, G. PY - 2006 DA - 2006// TI - Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia JO - Cancer. VL - 106 UR - https://doi.org/10.1002/cncr.21776 DO - 10.1002/cncr.21776 ID - Thomas2006 ER - TY - JOUR AU - Rizzieri, D. A. AU - Johnson, J. L. AU - Byrd, J. C. AU - Lozanski, G. AU - Blum, K. A. AU - Powell, B. L. PY - 2014 DA - 2014// TI - Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and leukemia group B study 10 002 JO - Br J Haematol VL - 165 UR - https://doi.org/10.1111/bjh.12736 DO - 10.1111/bjh.12736 ID - Rizzieri2014 ER - TY - JOUR AU - Maloney, D. G. PY - 2012 DA - 2012// TI - Anti-CD20 antibody therapy for B-cell lymphomas JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMct1114348 DO - 10.1056/NEJMct1114348 ID - Maloney2012 ER - TY - STD TI - Bazarbachi AH, Yilmaz M, Ravandi F, Thomas DA, Khouri M, Garcia-Manero G, et al. A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): updated results. J Clin Oncol. 2018;36(15_suppl):7041. ID - ref122 ER - TY - STD TI - Gökbuget N, Hoelzer D. Meningeosis leukaemica in adult acute lymphoblastic leukaemia. J Neurooncol. 1998;38(2):167–80. ID - ref123 ER - TY - JOUR AU - Lazarus, H. M. AU - Richards, S. M. AU - Chopra, R. AU - Litzow, M. R. AU - Burnett, A. K. AU - Wiernik, P. H. PY - 2006 DA - 2006// TI - Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993 JO - Blood. VL - 108 UR - https://doi.org/10.1182/blood-2005-11-4666 DO - 10.1182/blood-2005-11-4666 ID - Lazarus2006 ER - TY - JOUR AU - Reman, O. AU - Pigneux, A. AU - Huguet, F. AU - Vey, N. AU - Delannoy, A. AU - Fegueux, N. PY - 2008 DA - 2008// TI - Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group JO - Leuk Res VL - 32 UR - https://doi.org/10.1016/j.leukres.2008.04.011 DO - 10.1016/j.leukres.2008.04.011 ID - Reman2008 ER - TY - JOUR AU - Omura, G. A. AU - Moffitt, S. AU - Vogler, W. R. AU - Salter, M. M. PY - 1980 DA - 1980// TI - Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis JO - Blood. VL - 55 UR - https://doi.org/10.1182/blood.V55.2.199.199 DO - 10.1182/blood.V55.2.199.199 ID - Omura1980 ER - TY - JOUR AU - Sancho, J. M. AU - Ribera, J. M. AU - Oriol, A. AU - Hernandez-Rivas, J. M. AU - Rivas, C. AU - Bethencourt, C. PY - 2006 DA - 2006// TI - Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis JO - Cancer. VL - 106 UR - https://doi.org/10.1002/cncr.21948 DO - 10.1002/cncr.21948 ID - Sancho2006 ER - TY - STD TI - Pui C-H. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program. 2006;2006(1):142–6. ID - ref128 ER - TY - STD TI - Vora A, Andreano A, Pui CH, Hunger SP, Schrappe M, Moericke A, et al. Influence of cranial radiotherapy on outcome in children with acute lymphoblastic leukemia treated with contemporary therapy. J Clin Oncol. 2016;34(9):919–26. ID - ref129 ER - TY - JOUR AU - Larson, R. A. PY - 2018 DA - 2018// TI - Managing CNS disease in adults with acute lymphoblastic leukemia JO - Leuk Lymphoma VL - 59 UR - https://doi.org/10.1080/10428194.2017.1326597 DO - 10.1080/10428194.2017.1326597 ID - Larson2018 ER - TY - JOUR AU - Jabbour, E. AU - Thomas, D. AU - Cortes, J. AU - Kantarjian, H. M. AU - O’Brien, S. PY - 2010 DA - 2010// TI - Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies JO - Cancer. VL - 116 ID - Jabbour2010 ER - TY - JOUR AU - Patel, B. AU - Rai, L. AU - Buck, G. AU - Richards, S. M. AU - Mortuza, Y. AU - Mitchell, W. PY - 2010 DA - 2010// TI - Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 JO - Br J Haematol VL - 148 UR - https://doi.org/10.1111/j.1365-2141.2009.07941.x DO - 10.1111/j.1365-2141.2009.07941.x ID - Patel2010 ER - TY - JOUR AU - Gokbuget, N. AU - Kneba, M. AU - Raff, T. AU - Trautmann, H. AU - Bartram, C. R. AU - Arnold, R. PY - 2012 DA - 2012// TI - Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies JO - Blood. VL - 120 UR - https://doi.org/10.1182/blood-2011-09-377713 DO - 10.1182/blood-2011-09-377713 ID - Gokbuget2012 ER - TY - JOUR AU - Beldjord, K. AU - Chevret, S. AU - Asnafi, V. AU - Huguet, F. AU - Boulland, M. -. L. AU - Leguay, T. PY - 2014 DA - 2014// TI - Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia JO - Blood. VL - 123 UR - https://doi.org/10.1182/blood-2014-01-547695 DO - 10.1182/blood-2014-01-547695 ID - Beldjord2014 ER - TY - STD TI - Dhedin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125(16):2486–586. ID - ref135 ER - TY - JOUR AU - Bassan, R. AU - Masciulli, A. AU - Intermesoli, T. AU - Spinelli, O. AU - Tosi, M. AU - Pavoni, C. PY - 2016 DA - 2016// TI - Final results of Northern Italy leukemia group (NILG) trial 10/07 combining pediatric-type therapy with minimal residual disease study and risk-oriented hematopoietic cell transplantation in adult acute lymphoblastic leukemia (ALL) JO - Blood. VL - 128 UR - https://doi.org/10.1182/blood.V128.22.176.176 DO - 10.1182/blood.V128.22.176.176 ID - Bassan2016 ER - TY - JOUR AU - Della Starza, I. AU - Chiaretti, S. AU - Propris, M. S. AU - Elia, L. AU - Cavalli, M. AU - Novi, L. A. PY - 2019 DA - 2019// TI - Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances JO - Front Oncol VL - 9 UR - https://doi.org/10.3389/fonc.2019.00726 DO - 10.3389/fonc.2019.00726 ID - Della Starza2019 ER - TY - STD TI - Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017;1(25):2456–66. ID - ref138 ER - TY - JOUR AU - Wood, B. AU - Wu, D. AU - Crossley, B. AU - Dai, Y. AU - Williamson, D. AU - Gawad, C. PY - 2018 DA - 2018// TI - Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL JO - Blood. VL - 131 UR - https://doi.org/10.1182/blood-2017-09-806521 DO - 10.1182/blood-2017-09-806521 ID - Wood2018 ER - TY - JOUR AU - Short, N. J. AU - Jabbour, E. AU - Albitar, M. AU - Lima, M. AU - Gore, L. AU - Jorgensen, J. PY - 2019 DA - 2019// TI - Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts JO - Am J Hematol VL - 94 UR - https://doi.org/10.1002/ajh.25338 DO - 10.1002/ajh.25338 ID - Short2019 ER - TY - JOUR AU - Yilmaz, M. AU - Kantarjian, H. AU - Wang, X. AU - Khoury, J. D. AU - Ravandi, F. AU - Jorgensen, J. PY - 2020 DA - 2020// TI - The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival JO - Am J Hematol VL - 95 UR - https://doi.org/10.1002/ajh.25671 DO - 10.1002/ajh.25671 ID - Yilmaz2020 ER - TY - STD TI - Terwey TH, Hemmati PG, Nagy M, Pfeifer H, Gokbuget N, Bruggemann M, et al. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2014;20(10):1522–9. ID - ref142 ER - TY - JOUR AU - Zhao, X. S. AU - Liu, Y. R. AU - Zhu, H. H. AU - Xu, L. P. AU - Liu, D. H. AU - Liu, K. Y. PY - 2012 DA - 2012// TI - Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation JO - Ann Hematol VL - 91 UR - https://doi.org/10.1007/s00277-011-1285-1 DO - 10.1007/s00277-011-1285-1 ID - Zhao2012 ER - TY - JOUR AU - Giebel, S. AU - Stella-Holowiecka, B. AU - Krawczyk-Kulis, M. AU - Gökbuget, N. AU - Hoelzer, D. AU - Doubek, M. PY - 2010 DA - 2010// TI - Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL JO - Bone Marrow Transplant VL - 45 UR - https://doi.org/10.1038/bmt.2009.308 DO - 10.1038/bmt.2009.308 ID - Giebel2010 ER - TY - STD TI - FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse [Available from: https://www.fda.gov/news-events/press-announcements/fda-expands-approval-blincyto-treatment-type-leukemia-patients-who-have-certain-risk-factor-relapse. Accessed 30 Apr 2020. UR - https://www.fda.gov/news-events/press-announcements/fda-expands-approval-blincyto-treatment-type-leukemia-patients-who-have-certain-risk-factor-relapse ID - ref145 ER - TY - JOUR AU - Giebel, S. AU - Marks, D. I. AU - Boissel, N. AU - Baron, F. AU - Chiaretti, S. AU - Ciceri, F. PY - 2019 DA - 2019// TI - Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European working group for adult acute lymphoblastic leukemia (EWALL) and the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT) JO - Bone Marrow Transplant VL - 54 UR - https://doi.org/10.1038/s41409-018-0373-4 DO - 10.1038/s41409-018-0373-4 ID - Giebel2019 ER - TY - JOUR AU - Issa, G. C. AU - Kantarjian, H. M. AU - Yin, C. C. AU - Qiao, W. AU - Ravandi, F. AU - Thomas, D. PY - 2017 DA - 2017// TI - Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease JO - Cancer. VL - 123 UR - https://doi.org/10.1002/cncr.30376 DO - 10.1002/cncr.30376 ID - Issa2017 ER - TY - STD TI - Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K, Lengline E, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study. J Clin Oncol. 2013;31(34):4333–42. ID - ref148 ER - TY - JOUR AU - Hoelzer, D. AU - Gokbuget, N. PY - 2009 DA - 2009// TI - T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? JO - Clin Lymphoma Myeloma VL - 9 UR - https://doi.org/10.3816/CLM.2009.s.015 DO - 10.3816/CLM.2009.s.015 ID - Hoelzer2009 ER - TY - STD TI - Pehlivan KC, Duncan BB, Lee DW. CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease. Curr Hematol Malig Rep. 2018;13(5):396–406. ID - ref150 ER - TY - STD TI - Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, et al. Haploidentical transplantation with post-transplantation cyclophosphamide for high-risk acute lymphoblastic leukemia. Biol Blood Marrow transplant. 2017;23(2):318–24. ID - ref151 ER - TY - STD TI - Brissot E, Labopin M, Russo D, Martin S, Schmid C, Glass B, et al. Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2020. ID - ref152 ER - TY - STD TI - Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res. 2016;22(14):3467–76. ID - ref153 ER - TY - JOUR AU - Chang, Y. J. AU - Wang, Y. AU - Xu, L. P. AU - Zhang, X. H. AU - Chen, H. AU - Chen, Y. H. PY - 2020 DA - 2020// TI - Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study JO - J Hematol Oncol VL - 13 UR - https://doi.org/10.1186/s13045-020-00860-y DO - 10.1186/s13045-020-00860-y ID - Chang2020 ER - TY - JOUR AU - Rosko, A. AU - Wang, H. L. AU - Lima, M. AU - Sandmaier, B. AU - Khoury, H. J. AU - Artz, A. PY - 2017 DA - 2017// TI - Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia JO - Am J Hematol VL - 92 UR - https://doi.org/10.1002/ajh.24575 DO - 10.1002/ajh.24575 ID - Rosko2017 ER - TY - STD TI - Aldoss I, Forman SJ, Pullarkat V. Acute lymphoblastic leukemia in the older adult. J Oncol Pract. 2019;15(2):67–75. ID - ref156 ER - TY - JOUR AU - Roth-Guepin, G. AU - Canaani, J. AU - Ruggeri, A. AU - Labopin, M. AU - Finke, J. AU - Cornelissen, J. J. PY - 2017 DA - 2017// TI - Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.22934 DO - 10.18632/oncotarget.22934 ID - Roth-Guepin2017 ER - TY - JOUR AU - Qasim, W. AU - Allogeneic, C. A. R. PY - 2019 DA - 2019// TI - T cell therapies for leukemia JO - Am J Hematol VL - 94 UR - https://doi.org/10.1002/ajh.25399 DO - 10.1002/ajh.25399 ID - Qasim2019 ER - TY - JOUR AU - Fry, T. J. AU - Shah, N. N. AU - Orentas, R. J. AU - Stetler-Stevenson, M. AU - Yuan, C. M. AU - Ramakrishna, S. PY - 2018 DA - 2018// TI - CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy JO - Nat Med VL - 24 UR - https://doi.org/10.1038/nm.4441 DO - 10.1038/nm.4441 ID - Fry2018 ER - TY - STD TI - Amrolia PJ, Wynn R, Hough RE, Vora A, Bonney D, Veys P, et al. Phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD22, in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL): Amelia Study. Blood. 2019;134(Supplement_1):2620. ID - ref160 ER - TY - STD TI - Schultz LM, Muffly LS, Spiegel JY, Ramakrishna S, Hossain N, Baggott C, et al. Phase I trial using CD19/CD22 bispecific CAR T cells in pediatric and adult acute lymphoblastic leukemia (ALL). Blood. 2019;134(Supplement_1):744. ID - ref161 ER - TY - JOUR AU - Liu, E. AU - Marin, D. AU - Banerjee, P. AU - Macapinlac, H. A. AU - Thompson, P. AU - Basar, R. PY - 2020 DA - 2020// TI - Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors JO - N Engl J Med VL - 382 UR - https://doi.org/10.1056/NEJMoa1910607 DO - 10.1056/NEJMoa1910607 ID - Liu2020 ER - TY - STD TI - Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131(9):995-9. ID - ref163 ER - TY - JOUR AU - Ganzel, C. AU - Kharit, M. AU - Duksin, C. AU - Rowe, J. M. PY - 2018 DA - 2018// TI - Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia JO - Haematologica. VL - 103 UR - https://doi.org/10.3324/haematol.2018.197640 DO - 10.3324/haematol.2018.197640 ID - Ganzel2018 ER - TY - JOUR AU - Cooper, M. L. AU - Choi, J. AU - Staser, K. AU - Ritchey, J. K. AU - Devenport, J. M. AU - Eckardt, K. PY - 2018 DA - 2018// TI - An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies JO - Leukemia. VL - 32 UR - https://doi.org/10.1038/s41375-018-0065-5 DO - 10.1038/s41375-018-0065-5 ID - Cooper2018 ER - TY - STD TI - Wang SL X, Gao L, Yuan Z, Wu K, Liu L, Luo L, et al. Clinical safety and efficacy study of TruUCAR™ GC027: the first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). American Association for Cancer Research (AACR) Virtual Annual Meeting I; April 27-28, 2020. ID - ref166 ER -